Nonvitamin K antagonist oral anticoagulants (NOACs): The tide continues to come in

Vascular Health and Risk Management

Volumn 11, Issue , 2015, Pages 489-492

  Blann, Andrew ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ANDEXANET ALFA; ANTIVITAMIN K; APIXABAN; BETRIXABAN; CIRAPARANTAG; DABIGATRAN; DAREXABAN; DIGOXIN; FONDAPARINUX; HEPARIN; IDARUCIZUMAB; LOW MOLECULAR WEIGHT HEPARIN; NONVITAMIN K ANTAGONIST ORAL ANTICOAGULANT; PHENOCOUMAROL; RIFAMPICIN; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; ANTICOAGULANT AGENT; NEW DRUG;

ACUTE CORONARY SYNDROME; ATRIAL FIBRILLATION; BLEEDING; BLOOD COMPONENT THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; EMERGENCY SURGERY; ENZYME ACTIVITY; HUMAN; IN VIVO STUDY; LIVER DISEASE; LUNG EMBOLISM; MORBIDITY; MORTALITY; ORTHOPEDIC SURGERY; PARTIAL THROMBOPLASTIN TIME; URINARY EXCRETION; VENOUS THROMBOEMBOLISM; ANIMAL; BLOOD; BLOOD CLOTTING; CHEMICALLY INDUCED; DRUG EFFECTS; ORAL DRUG ADMINISTRATION; RISK ASSESSMENT; RISK FACTOR; THROMBOSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DRUGS, INVESTIGATIONAL; HEMORRHAGE; HUMANS; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84940108929     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S89736     Document Type: Editorial

References (36)

1. ISTH Stpering Committee for World Thrombosis Day. Thrombosis: a major contributor to the global disease burden. J Thromb Haemost. 2014;12:1580–1590.
2. Blann AD, Khoo CW. The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. Vasc Health Risk Manag. 2009;5:693–704.
3. Riva N, Ageno W. Pros and cons of vitamin K antagonists and non-vitamin K antagonist oral anticoagulants. Semin Thromb Hemost. 2015;41:178–187.
4. Husted S, De Caterina R, Andreotti F, et al. ESC Working Group on Thrombosis Task Force on anticoagulants in heart disease. Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost. 2014;111:781–782.
5. Stangier J, Rathgen K, Stahle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64:292–303.
6. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78: 412–421.
7. Wong PC, Crain EJ, Xin B, et al. Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies. J Thromb Haemost. 2008;6:820–829.
8. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxabanin healthy volunteers. J Clin Pharmacol. 2010;50: 743–753.
9. Ahrens I, Peter K, Lip GY, Bode C. Development and clinical applications of novel oral anticoagulants. Part II. Drugs under clinical investigation. Discov Med. 2012;13:445–450.
10. Caldeira D, Barra M, Santos AT, et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014;100:550–556.
11. Palladino M, Merli G, Thomson L. Evaluation of the oral direct factor Xa inhibitor – betrixaban. Expert Opin Investig Drugs. 2013;22: 1465–1472.
12. Iwatsuki Y, Sato T, Moritani Y, et al. Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. Eur J Pharmacol. 2011;673:49–55.
13. Hashimoto T, Suzuki K, Kihara Y, et al. Absorption, metabolism and excretion of darexaban (YM150), a new direct factor Xa inhibitor in humans. Xenobiotica. 2013;43(6):534–547.
14. Kaku S, Suzuki M, Saitoh M, et al. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa. Thromb Res. 2013;131:450–456.
15. Kadokura T, Groenendaal D, Heeringa M, et al. Darexaban (YM150), an oral direct factor Xa inhibitor, has no effect on the pharmacokinetics of digoxin. Eur J Drug Metab Pharmacokinet. 2014;39:1–9.
16. Groenendaal D, Strabach G, Garcia-Hernandez A, et al. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4. Br J Clin Pharmacol. 2013;75(2):440–449.
17. Sakon M, Nakamura M. Darexaban (YM150) prevents venous thromboembolism in Japanese patients undergoing major abdominal surgery: phase III randomized, mechanical prophylaxis-controlled, open-label study. Thromb Res. 2012;130:e52–e59.
18. Fuji T, Nakamura M, Takeuchi M. Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies. Clin Appl Thromb Hemost. 2014;20:199–211.
19. Eriksson BI, Agnelli G, Gallus AS, et al. Darexaban (YM150) versus enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a randomised phase IIb dose confirmation study (ONYX-3). Thromb Haemost. 2014;111:213–225.
20. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1 investigators. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J. 2011;32:2541–2554.
21. Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.
22. Ganetsky VS, Hadley DE, Thomas TF. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes. Pharmacotherapy. 2014;34:590–604.
23. Chan NC, Bhagirath V, Eikelboom JW. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015;11:343–351.
24. Greinacher A, Thiele T, Selleng K. Reversal of anticoagulants: an overview of current developments. Thromb Haemost. 2015;113:931–942.
25. Glund S, Moschetti V, Norris S, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113:943–951.
26. Pollack CV Jr, Reilly PA, Bernstein R, et al. Design and rationale for RE-VERSE AD: a phase 3 study of idarucizumab, a specific reversal agent for dabigatran. Thromb Haemost. 2015;114(1):198–205.
27. Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446–451.
28. Fawole A, Daw HA, Crowther MA. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban. Cleve Clin J Med. 2013;80:443–451.
29. Holster IL, Hunfield NGM, Kuipers EJ, Kruip MJHA, Tjwa ETTL. On the treatment of new oral anticoagulant-associated gastrointestinal haemorrhage. J Gastrointestin Liver Dis. 2013;22:229–231.
30. Majeed A, Schulman S. Bleeding and antidotes in new oral anticoagulants. Best Pract Res Clin Haematol. 2013;26:191–202.
31. Steiner T, Bohm M, Dichgans M, et al. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs) apixaban, dabigatran and rivaroxaban. Clin Res Cardiol. 2013;102:399–412.
32. Cushman M, Lim W, Zakai NA. Clinical Practice Guide on Antithrombotic Drug Dosing and Management of Anti-Thrombotic Drug-Associated Bleeding Complications in Adults. 2014. Available from: http://www.hematology.org/Clinicians/Guidelines-Quality/Quick-Ref/2869.aspx. February 2014 Edition. Accessed August 3, 2015.
33. Dinkelaar J, Patiwael S, Harenberg J, Leyte A, Brinkman HJ. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med. 2014;52:1615–1623.
34. Blann AD. Non-vitamin K antagonist oral anticoagulants (NOACs): a view from the laboratory. Br J Biomed Sci. 2014;71:158–167.
35. Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the ISTH. J Thromb Haemost. 2013;11:756–760.
36. Kitchen S, Gray E, Mackie I, Baglin T, Makris M. Measurement of non-coumarin anticoagulants and their effects on tests of haemostasis: guidance from the British Committee for standards in haematology. Br J Haematol. 2014;166:830–841.